Payment overview · 2025
General Payments
$153.57
10 reported records · 7 companies
Healthcare provider profile · identity verified
Patrick Brian Gipe, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OWENSBORO, KY · NPI 1598761702
Verified facts
What the public records show
CMS Open Payments records show Patrick Brian Gipe, M.D. received $153.57 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.36 | 23.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.47 | 19.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.45 | 18.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.46 | 10.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.25 | 9.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.90 | 9.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.68 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $153.57 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $30.15 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.47 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 200 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
200 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 910 | 212 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 764 | 196 |
| Pantoprazole Sodium | Pantoprazole Sodium | 625 | 153 |
| Losartan Potassium | Losartan Potassium | 529 | 134 |
| Levothyroxine Sodium | Levothyroxine Sodium | 518 | 121 |
| Simvastatin | Simvastatin | 469 | 126 |
| Atorvastatin Calcium | Atorvastatin Calcium | 404 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 403 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 357 | 85 |
| Lisinopril | Lisinopril | 341 | 79 |
| Furosemide | Furosemide | 332 | 83 |
| Gabapentin | Gabapentin | 297 | 65 |
| Celecoxib | Celecoxib | 284 | 73 |
| Alprazolam | Alprazolam | 274 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 267 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 225 | 51 |
| Potassium Chloride | Potassium Chloride | 217 | 59 |
| Omeprazole | Omeprazole | 212 | 53 |
| Eliquis | Apixaban | 209 | 35 |
| Glipizide Er | Glipizide | 207 | 47 |
| Sertraline Hcl | Sertraline Hcl | 207 | 44 |
| Ozempic | Semaglutide | 200 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 195 | 46 |
| Ipratropium Bromide | Ipratropium Bromide | 189 | 81 |
| Alendronate Sodium | Alendronate Sodium | 184 | 43 |
| Buspirone Hcl | Buspirone Hcl | 184 | 40 |
| Trazodone Hcl | Trazodone Hcl | 176 | 48 |
| Metformin Hcl Er | Metformin Hcl | 175 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 35 |
| Synthroid | Levothyroxine Sodium | 155 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 155 | 51 |
| Metformin Hcl | Metformin Hcl | 154 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 152 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 60 |
| Prednisone | Prednisone | 151 | 103 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | 32 |
| Tramadol Hcl | Tramadol Hcl | 135 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 27 |
| Allopurinol | Allopurinol | 130 | 32 |
| Meloxicam | Meloxicam | 126 | 28 |
| Pregabalin | Pregabalin | 116 | 28 |
| Clonazepam | Clonazepam | 115 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 27 |
| Temazepam | Temazepam | 109 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 24 |
| Spironolactone | Spironolactone | 99 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 95 | 21 |
| Finasteride | Finasteride | 93 | 18 |
| Farxiga | Dapagliflozin Propanediol | 87 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 18 |
| Warfarin Sodium | Warfarin Sodium | 81 | 18 |
| Promethazine Hcl | Promethazine Hcl | 80 | 11 |
| Bupropion Xl | Bupropion Hcl | 79 | 17 |
| Carvedilol | Carvedilol | 77 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 71 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 68 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 67 | 54 |
| Estradiol | Estradiol | 65 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 13 |
| Atenolol | Atenolol | 64 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 21 |
| Xarelto | Rivaroxaban | 61 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 60 | 23 |
| Ezetimibe | Ezetimibe | 57 | 16 |
| Fenofibrate | Fenofibrate | 57 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Famotidine | Famotidine | 54 | 16 |
| Jardiance | Empagliflozin | 54 | suppressed |
| Topiramate | Topiramate | 53 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 50 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 14 |
| Digoxin | Digoxin | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 14 |
| Valsartan | Valsartan | 46 | 15 |
| Klor-Con M20 | Potassium Chloride | 45 | 18 |
| Risperidone | Risperidone | 45 | 11 |
| Doxepin Hcl | Doxepin Hcl | 44 | suppressed |
| Myrbetriq | Mirabegron | 44 | 11 |
| Diazepam | Diazepam | 43 | 11 |
| Lorazepam | Lorazepam | 43 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 14 |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 32 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Lovastatin | Lovastatin | 40 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 18 |
| Colchicine | Colchicine | 39 | 15 |
| Lansoprazole | Lansoprazole | 39 | 11 |
| Sucralfate | Sucralfate | 39 | 18 |
| Valacyclovir | Valacyclovir Hcl | 39 | 16 |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 14 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 22 |
| Primidone | Primidone | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 17 |
| Glipizide | Glipizide | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 14 |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Triazolam | Triazolam | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 11 |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $153.57 · 10 records | Amgen Inc. | AREXVY, Cologuard Collection Kit, EVENITY, JARDIANCE, Ozempic, PROLIA, Rybelsus, TRELEGY ELLIPTA, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error